Key Drivers
- Strong Margins
- Solid Cash Flow
- Rich Valuation
AIAI Summary
Agilent still has high-quality pharma/diagnostics momentum and clean near-term catalysts, but the stock should now be treated as a “show-me” name because rich valuation plus recent margin pressure mean the next earnings print and Biocare integration must prove growth and profitability can broaden without further compression.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Margins
- •Solid Cash Flow
- •Rich Valuation
A has a strong, cash-generative core business with solid returns and liquidity, but its rich valuation, meaningful leverage, and large intangible asset base limit upside and increase risk.
Price Behavior
Key Price Behavior Insights:
- •Support holding
- •Lower highs
- •Rally failure
A has shifted into a clear short-term downtrend over the last month, with repeated support near $111 but persistent failures below $115-$122 keeping rallies vulnerable unless resistance breaks.
Rebound into 2026-05-07 showed quick recovery when selling eased
Sentiment & News
Key News Insights:
- •Buy upgrade
- •Earnings catalyst
- •Institutional trims
Agilent's improved earnings outlook, upcoming Q2 results and conference appearance, and cleaner legal backdrop support a constructive near-term setup, though recent institutional selling suggests some caution.
The news is mildly positive for Agilent in the near term, with catalysts and governance improvements likely outweighing the modest negative signal from recent share sales
Similar Companies in Healthcare
Other companies in the same sector with AI ratings